Tradestie Institutional Equity Comparison Engine
CVM vs DCTH โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DCTH Overall Edge
DCTH Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Delcath Systems Inc (DCTH) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, CVM trades at 23.0x Forward P/E with 0.0% operating margin (-62.7% YoY revenue) versus DCTH at N/M Forward P/E and 5.2% operating margin (+70.7% YoY). In options structure, CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against DCTH sits in BREAKOUT (43rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CVM
CVM 23.0x vs DCTH N/M Fwd P/E
Growth & Margin Winner
DCTH
Op Margin 0.0% vs 5.2% ยท YoY -62.7% vs +70.7%
Momentum & Technical Winner
DCTH
1Y -77.5% vs +128.6% ยท 52W Pos 10% vs 80%
Options & Structure Winner
DCTH
BREAKDOWN (N/A IV) vs BREAKOUT (43rd %ile IV)
CVM
NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap
$20.9M
1M Return
-11.17%
1Y Return
-77.48%
Forward P/E
23.0x
Unified AI Score
56.6 / 100
HOLD
Tech 60.0
Fund 54.0
Flow 50.0
Mom 60.0
DCTH
NASDAQ
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap
$743.8M
1M Return
+39.77%
1Y Return
+128.57%
Forward P/E
N/M
Unified AI Score
35.9 / 100
SELL
Tech 50.0
Fund 38.0
Flow 60.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CVM -77.48%
DCTH +128.57%
Spread: +196.36 pp (DCTH Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CVM Revenue | DCTH Revenue | CVM Op. Margin | DCTH Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2013 | $0M | $0M | -12450.1% | -4179.6% | DCTH |
| FY2014 | $0M | $0M | -9721.4% | -1805.8% | DCTH |
| FY2015 | N/A | $0M | N/A | -870.6% | DCTH |
| FY2021 | N/A | $0M | N/A | -690.0% | DCTH |
| FY2022 | N/A | $0M | N/A | -1245.1% | DCTH |
| FY2023 | N/A | $0M | N/A | -1849.0% | DCTH |
| FY2024 | N/A | $40M | N/A | -33.4% | DCTH |
| FY2025 | N/A | $90M | N/A | 0.8% | DCTH |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CVM | DCTH | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $20.9M | $743.8M | Larger Scale | DCTH |
| Trailing P/E Ratio Valuation | 23.0x | 133.6x | Lower Multiple | CVM |
| Forward P/E Ratio Valuation | 23.0x | N/M | Lower Multiple | CVM |
| Revenue Growth (YoY) Growth | -62.7% | +70.7% | Higher Growth | DCTH |
| Operating Margin (TTM) Profitability | 0.0% | 5.2% | Higher Margin | DCTH |
| Net Profit Margin Profitability | 0.0% | 6.0% | Higher Margin | DCTH |
| Return on Equity (ROE) Capital Efficiency | -252.5% | 5.4% | Higher ROE | DCTH |
| 52-Week Range Position Momentum | 10% ($1โ$8) | 80% ($8โ$23) | Stronger Trend | DCTH |
| Beta / 30D Volatility Risk Regime | 0.65ฮฒ ยท 120% Vol | 1.63ฮฒ ยท 131% Vol | Lower Realized Risk | CVM |
| Unified Institutional Score Composite Signal | 56.6 / 100 (HOLD) | 35.9 / 100 (SELL) | Higher Composite | CVM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CVM vs DCTH Buy Guide
CVM
BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
DCTH
BREAKOUT
66d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
43rd %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CVM nor DCTH registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.